One of the major findings of our study is that targeting HER-2 with Trastuzumab-DM1, an antibody-drug conjugate developed to improve the treatment of HER-2 positive breast cancer, may offer a new therapeutic approach in lung cancers expressing HER-2 even when resistant to EGFR TKIs. This evidence concerns the gene ERBB2 and lung cancer.